Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gimsing

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Haematologica|May 12, 2004
A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myelomaAnne-Tove Brenne, Lene Hejna Romstad, Peter Gimsing, et al.
European Journal of Haematology|January 10, 2008
High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patientsAnne K Mylin, Niels Abildgaard, Julia S Johansen, et al.
Annals of Hematology|February 25, 2011
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomibAnnette J Vangsted, Tobias W Klausen, Niels Abildgaard, et al.
European Journal of Haematology|May 19, 2010
Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004Annette J Vangsted, Tobias W Klausen, Niels F Andersen, et al.
Annals of Hematology|November 4, 2010
The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAPAnnette J Vangsted, Tobias Wirenfeldt Klausen, Peter Gimsing, et al.
International Journal of Cancer|November 30, 2006
Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantationAnnette Vangsted, Peter Gimsing, Tobias W Klausen, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 17, 2010
Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study groupHans E Johnsen, Tobias W Klausen, Martin Boegsted, et al.
British Journal of Haematology|April 3, 2004
Early response predicts thalidomide efficiency in patients with advanced multiple myelomaAnders Waage, Peter Gimsing, Gunnar Juliusson, et al.
BMC Cancer|August 6, 2010
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple MyelomaAnnette J Vangsted, Karen Søeby, Tobias W Klausen, et al.
Acta Haematologica|April 1, 2015
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groupsMeral Beksac, Anders Waage, Sara Bringhen, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Haematologica|May 12, 2004
A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myelomaAnne-Tove Brenne, Lene Hejna Romstad, Peter Gimsing, et al.
European Journal of Haematology|January 10, 2008
High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patientsAnne K Mylin, Niels Abildgaard, Julia S Johansen, et al.
Annals of Hematology|February 25, 2011
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomibAnnette J Vangsted, Tobias W Klausen, Niels Abildgaard, et al.
European Journal of Haematology|May 19, 2010
Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004Annette J Vangsted, Tobias W Klausen, Niels F Andersen, et al.
Annals of Hematology|November 4, 2010
The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAPAnnette J Vangsted, Tobias Wirenfeldt Klausen, Peter Gimsing, et al.
International Journal of Cancer|November 30, 2006
Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantationAnnette Vangsted, Peter Gimsing, Tobias W Klausen, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 17, 2010
Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study groupHans E Johnsen, Tobias W Klausen, Martin Boegsted, et al.
British Journal of Haematology|April 3, 2004
Early response predicts thalidomide efficiency in patients with advanced multiple myelomaAnders Waage, Peter Gimsing, Gunnar Juliusson, et al.
BMC Cancer|August 6, 2010
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple MyelomaAnnette J Vangsted, Karen Søeby, Tobias W Klausen, et al.
Acta Haematologica|April 1, 2015
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groupsMeral Beksac, Anders Waage, Sara Bringhen, et al.
Pageof 6